Data protection Impressum

R&D

Researchers from the Francis Crick Institute and Bern-based AlveoliX have developed the first human lung-on-chip model built entirely from genetically identical cells, opening new perspectives for personalised respiratory disease research.

AlveoliX contributes to first lung-on-chip model using genetically identical human cells

19 January 2026

Researchers at CHUV have validated a new stem-cell–based method to study autoimmune diseases in organs such as the brain, offering new insights into conditions like autoimmune encephalitis and multiple sclerosis.

CHUV researchers develop new method to study autoimmune diseases

2 December 2025

Researchers from Western Switzerland have unveiled the first fully compostable smart sensor to monitor temperature-sensitive goods, offering a sustainable alternative to conventional tags.

EPFL, Empa and CSEM develop the first fully compostable smart sensor

2 December 2025

Switzerland re-associates to Horizon Europe, Euratom and Digital Europe

11 November 2025

Supported by Innosuisse, CSEM spin-off CCRAFT is expanding its TFLN foundry to meet growing global demand for high-performance chips powering AI and data centers.

CCRAFT invests EUR 2.7 million to scale up photonic chip production in Neuchâtel

10 November 2025

Despite growing global trade tensions, Switzerland maintains its leadership in digital competitiveness, ahead of the US and Singapore.

Business environment

Switzerland tops IMD’s 2025 Digital Competitiveness Ranking

10 November 2025

A world-class ecosystem where research, education, and industry converge to shape the future of sustainable production.

Fribourg, Switzerland’s hub for digital manufacturing

Neurotechnology company ONWARD Medical extends its cash runway through 2026 and prepares to expand commercialization and clinical development of its ARC Therapy systems.

ONWARD Medical raises over EUR 50 million to advance spinal cord therapies

27 October 2025

Vaud-based FemTech company Aspivix begins commercial rollout in Southern California and New York following strong clinical validation and growing U.S. demand.

Aspivix launches its breakthrough Carevix device in the United States

21 October 2025

Lausanne-based biotech ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.

ADC Therapeutics raises USD 60 million to strengthen oncology portfolio

21 October 2025

1 2 3 4 5 … 17